Cercar
14/04/2023
Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI
Redondo, S, Garcia-Cadenas, I, Vila, A, Esquirol, A, Portos, JM, Novelli, S, Saavedra, S, Moreno, C, Garrido, A, Arguello-Tomas, M, Onate, G, Lopez-Pardo, J, Caballero, AC, Miqueleiz, S, Briones, J, Sierra, J, Sancho, G, Martino, R. Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI. EUROPEAN JOURNAL OF HAEMATOLOGY. 2023; 111(1)DOI:10.1111/ejh.13978. PMID:37058419. IF:2.300(Q2/5D).
01/04/2023
Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus
Bonet, M, Gonzalez, D, Baquedano, JE, Garcia, E, Altabas, M, Casas, F, Feltes, N, Ferrer, F, Foro, P, Fuentes, R, Galdeano, M, Gomez, D, Henriquez, I, Jove, J, Lozano, J, Maldonado, X, Mases, J, Membrive, I, Paredes, S, Rosello, A, Sancho, G, Mira, M. Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus. Clinical & Translational Oncology. 2023; 25(4)DOI:10.1007/s12094-022-03005-4. PMID:36436177. IF:2.800(Q2/5D).
01/01/2023
Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)
Pérez-Fidalgo J.A., Ortega E., Ponce J., Redondo A., Sevilla I., Valverde C., Verdum, JI, de Alava E., Lopez, MG, Marquina G., Sebio A.. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS). Therapeutic Advances in Medical Oncology. 2023; 15DOI:10.1177/17588359231157645. PMID:37007636. IF:4.300(Q2/3D).
01/11/2022
Prognostic value of transcriptional expression of fibronectin type III domain-containing 4 (FNDC4) in head and neck carcinoma patients treated with chemoradiotherapy
Camacho, M, Leon, X, Pujol, A, Montezuma, L, Quer, M, Garcia, J. Prognostic value of transcriptional expression of fibronectin type III domain-containing 4 (FNDC4) in head and neck carcinoma patients treated with chemoradiotherapy. Clinical & Translational Oncology. 2022; 24(11)DOI:10.1007/s12094-022-02870-3. PMID:35752749. IF:3.400(Q3/6D).
01/08/2022
Evidence-based guidelines for hypofractionated radiation in breast cancer: conclusions of the Catalan expert working group
Eraso, A, Sanz, J, Molla, M, Reyes, V, Pedro, A, Arenas, M, Martinez, E, Ballester, R, Cambra, MJ, Garcia, V, Prades, JL, Borras, JM, Algara, M. Evidence-based guidelines for hypofractionated radiation in breast cancer: conclusions of the Catalan expert working group. Clinical & Translational Oncology. 2022; 24(8)DOI:10.1007/s12094-022-02798-8. PMID:35190961. IF:3.400(Q3/6D).
22/07/2022
Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study
Suarez, JF, Zamora, V, Garin, O, Gutierrez, C, Pont, A, Pardo, Y, Goni, A, Marino, A, Hervas, A, Herruzo, I, Cabrera, P, Sancho, G, de Leon, JP, Macias, V, Guedea, F, Vigues, F, Castells, M, Ferrer, M. Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-16395-w. PMID:35869124. IF:4.600(Q2/4D).
14/07/2022
Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer
Lara, PC, Rodriguez-Melcon, JI, Palacios-Eito, A, Lozano, A, Hervas-Moron, A, Villafranca, E, Gomez-Iturriaga, A, Sancho, G, Maldonado, X. Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer. Frontiers in Oncology. 2022; 12DOI:10.3389/fonc.2022.891886. PMID:35912190. IF:4.700(Q2/4D).
01/06/2022
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
Rodríguez F., Caruana P., De la Fuente N., Español P., Gámez M., Balart J., Llurba E., Rovira R., Ruiz R., Martín-Lorente C., Corchero J.L., Céspedes M.V.. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules. 2022; 12(6)DOI:10.3390/biom12060784. PMID:35740909. IF:5.500(Q1/3D).